Currently, Maravai LifeSciences Holdings Inc [MRVI] is trading at $5.93, up 9.21%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The MRVI shares have gain 9.81% over the last week, with a monthly amount glided 16.85%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Maravai LifeSciences Holdings Inc [NASDAQ: MRVI] stock has seen the most recent analyst activity on December 05, 2024, when Goldman downgraded its rating to a Sell but kept the price target unchanged to $4.25 for it. On November 08, 2024, downgrade downgraded it’s rating to Mkt Perform. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $10 on August 28, 2024. Morgan Stanley downgraded its rating to a Equal-Weight and reduced its price target to $10 on August 13, 2024. Craig Hallum started tracking with a Buy rating for this stock on April 10, 2024, and assigned it a price target of $15. In a note dated December 12, 2023, BofA Securities upgraded an Buy rating on this stock and revised its target price from $10 to $8.
This stock has fluctuated between a low of $4.28 and a high of $11.56 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $19 within the next 12 months. Maravai LifeSciences Holdings Inc [NASDAQ: MRVI] shares were valued at $5.93 at the most recent close of the market. An investor can expect a potential return of 220.4% based on the average MRVI price forecast.
Analyzing the MRVI fundamentals
Trailing Twelve Months sales for Maravai LifeSciences Holdings Inc [NASDAQ:MRVI] were 276.92M which represents -2.49% decline. Gross Profit Margin for this corporation currently stands at 0.44% with Operating Profit Margin at -0.71%, Pretax Profit Margin comes in at 1.59%, and Net Profit Margin reading is -0.81%. To continue investigating profitability, this company’s Return on Assets is posted at -0.18, Equity is -0.56 and Total Capital is -0.16. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.51.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.58 points at the first support level, and at 5.22 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.18, and for the 2nd resistance point, it is at 6.42.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Maravai LifeSciences Holdings Inc [NASDAQ:MRVI] is 10.74. Also, the Quick Ratio is 9.94, while the Cash Ratio stands at 9.14. Considering the valuation of this stock, the price to sales ratio is 5.41, the price to book ratio is 2.43.
Transactions by insiders
Recent insider trading involved DeFord John A, Director, that happened on Nov 12 ’24 when 17500.0 shares were purchased., HULL CARL completed a deal on Nov 11 ’24 to buy 0.17 million shares. Meanwhile, Director GTCR INVESTMENT XI LLC sold 9.94 million shares on May 28 ’24.
